A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

  • End date
    Mar 31, 2023
  • participants needed
  • sponsor
    Insmed Incorporated
Updated on 26 May 2022


The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH)

Condition Pulmonary Arterial Hypertension
Treatment Treprostinil Palmitil
Clinical Study IdentifierNCT04791514
SponsorInsmed Incorporated
Last Modified on26 May 2022


Yes No Not Sure

Inclusion Criteria

Participant must be ≥ 18 years of age at the time of signing the informed consent
Participants must have a diagnosis of World Health Organization Group 1 Pulmonary Hypertension (PH) (PAH) with the following characteristics
Etiology of idiopathic, heritable, drug/toxin-induced or connective tissue disease (CTD)-related PAH
Right heart catheterization with the following hemodynamic findings
Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest
No change in diuretic use or dosage for at least 30 days prior to Screening
Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and
Pulmonary vascular resistance (PVR) of ≥ 3 Wood Units (WU)
Male participants: Male participants and their female partners of childbearing potential must agree to use highly effective contraception from Study Day 1 to at least 90 days after dosing
No change in pulmonary hypertension medications (eg, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, riociguat) or dosage for at least 90 days prior to Screening
Female participants: Women of child-bearing potential (WOCPB, defined as premenopausal, not surgically sterile for at least 3 months prior to Screening) must use a highly effective contraception method and agree to be tested for pregnancy from at Screening, Baseline, and 30 days after dosing
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Body mass index (BMI) within the range 18.0 - 32.0 kg/m^2 (inclusive)

Exclusion Criteria

Any PH other than idiopathic, hereditary, drug/toxin-induced, or connective tissue disease (CTD) associated PAH (eg, congenital heart disease-associated PAH, portal hypertension-associated PAH, PH belonging to Groups 2 through 5)
Allergy, or documented hypersensitivity or contraindication, to the ingredients of treprostinil palmitil inhalation powder (TPIP) or treprostinil (TRE)
Previous intolerance to prostacyclin analogs or receptor agonists (eg, selexipag) per investigator discretion
History of anaphylaxis or previously documented hypersensitivity reaction to any drug per Investigator discretion
History of heart disease including left ventricular ejection fraction (LVEF) ≤ 40% or clinically significant valvular, constrictive, or atherosclerotic heart disease (myocardial infarction, etc)
History of HIV infection/positive HIV serology test result at Screening
History of active/chronic Hepatitis B or C/ positive hepatitis B or C serology test result at Screening
Active liver disease or hepatic dysfunction manifested as
History of abnormal bleeding or bruising
Elevated liver function test results (ALT or AST > 2 × ULN) at Screening
Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the investigator
Bilirubin > 1.5 × ULN (isolated bilirubin > 1.5 × ULN; ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) at Screening
Active and current symptomatic infection by SARS CoV 2
Known hepatic or biliary abnormalities, not including Gilbert's syndrome or asymptomatic gallstones at Screening
Participants with current or recent (past 4 weeks) lower respiratory tract infection
History of malignancy in the past 5 years, with exception of completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin
Participants receiving triple combination therapy for PAH consisting of endothelin receptor agonists, phosphoesterase type 5 inhibitors, and guanylate cyclase stimulators (riociguat)
Participants receiving prostanoids/prostacyclin agonists
Participants receiving potent CYP2C8 inhibitors, such as gemfibrozil
Have participated in any other interventional clinical studies within 30 days of Baseline
Current or history of substance and/or alcohol abuse
Current user of cigarettes or e-cigarettes
Pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note